Greek-founded, NY-based Keragon, an AI-powered healthcare automation platform, secured a €7.2 million seed round from Upfront Ventures, Afore Capital, Focal, and 25m Health.
👯 Founders: Conno Christou, George Makkoulis, Panos Papageorgiou, George Eracleous
📅 Founding year: 2024
🏭 Industry: Healthcare automation, AI, and workflow automation
💥 Problem: Healthcare providers and staff struggle with disconnected point solutions, leading to inefficiencies, administrative burdens, and slower patient care.
📣 Solution: Keragon provides a HIPAA-compliant, no-code workflow automation platform that seamlessly integrates 300+ healthcare tools, reducing manual work and improving efficiency.
👥 Customers: Healthcare providers, including solo practices, digital health companies, multi-location clinics, and hospitals.
🌱 Stage: Seed
💰 Investment amount: €7.2 million
🚀 Funded by: Upfront Ventures (lead), Afore Capital, Focal, and 25m Health
👁️🗨️ Investor’s perspective: “Healthcare providers are weighed down by fragmented systems. Keragon turns this into a connected ecosystem, saving clinics hours of manual work.” – Kevin Zhang, Partner at Upfront Ventures
💡 It will be spent on: Accelerating AI-driven automation development, expanding the engineering and customer success teams.
💬 In their own words: “Keragon is like Zapier for healthcare, but HIPAA-compliant and way faster.” – Kevin Bundy, CEO of Alive IV and Wellness
💪 Their specialty: No-code workflow automation for healthcare, with a strong emphasis on seamless integrations and AI-powered efficiency.
🔑 Business model: SaaS platform offering automation and integration solutions for healthcare providers.
👩🏫 Market: Healthcare professionals seeking efficient, compliant automation solutions to streamline operations.
📊 Traction: 100+ paying customers, 30% month-over-month growth, 2M+ workflow automations executed since launch.
⚡Competitors: Companies providing healthcare workflow automation, integration solutions, or general automation platforms like Zapier (but without HIPAA compliance).
